COVID-19 Impact on Global Anti-Parkinson Drugs Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Anti-Parkinson Drugs Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global Anti-Parkinson Drugs Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Dopaminergic
  • 1.4.3 Dopamine Agonists
  • 1.4.4 Enzyme Inhibitors
  • 1.4.5 Others
• 1.5 Market by Application
  • 1.5.1 Global Anti-Parkinson Drugs Market Share by Application: 2020 VS 2026
  • 1.5.2 Hospital Pharmacy
  • 1.5.3 Retail Pharmacy
  • 1.5.4 Online Stores
• 1.6 Coronavirus Disease 2019 (Covid-19): Anti-Parkinson Drugs Industry Impact
  • 1.6.1 How the Covid-19 is Affecting the Anti-Parkinson Drugs Industry
    • 1.6.1.1 Anti-Parkinson Drugs Business Impact Assessment - Covid-19
    • 1.6.1.2 Supply Chain Challenges
    • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  • 1.6.2 Market Trends and Anti-Parkinson Drugs Potential Opportunities in the COVID-19 Landscape
  • 1.6.3 Measures / Proposal against Covid-19
    • 1.6.3.1 Government Measures to Combat Covid-19 Impact
    • 1.6.3.2 Proposal for Anti-Parkinson Drugs Players to Combat Covid-19 Impact
• 1.7 Study Objectives
• 1.8 Years Considered

2 Global Growth Trends by Regions

• 2.1 Anti-Parkinson Drugs Market Perspective (2015-2026)
• 2.2 Anti-Parkinson Drugs Growth Trends by Regions
  • 2.2.1 Anti-Parkinson Drugs Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Anti-Parkinson Drugs Historic Market Share by Regions (2015-2020)
  • 2.2.3 Anti-Parkinson Drugs Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Anti-Parkinson Drugs Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Anti-Parkinson Drugs Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Anti-Parkinson Drugs Players by Market Size
  • 3.1.1 Global Top Anti-Parkinson Drugs Players by Revenue (2015-2020)
  • 3.1.2 Global Anti-Parkinson Drugs Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Anti-Parkinson Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Anti-Parkinson Drugs Market Concentration Ratio
  • 3.2.1 Global Anti-Parkinson Drugs Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Anti-Parkinson Drugs Revenue in 2019
• 3.3 Anti-Parkinson Drugs Key Players Head office and Area Served
• 3.4 Key Players Anti-Parkinson Drugs Product Solution and Service
• 3.5 Date of Enter into Anti-Parkinson Drugs Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global Anti-Parkinson Drugs Historic Market Size by Type (2015-2020)
• 4.2 Global Anti-Parkinson Drugs Forecasted Market Size by Type (2021-2026)

5 Anti-Parkinson Drugs Breakdown Data by Application (2015-2026)

• 5.1 Global Anti-Parkinson Drugs Market Size by Application (2015-2020)
• 5.2 Global Anti-Parkinson Drugs Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Anti-Parkinson Drugs Market Size (2015-2020)
• 6.2 Anti-Parkinson Drugs Key Players in North America (2019-2020)
• 6.3 North America Anti-Parkinson Drugs Market Size by Type (2015-2020)
• 6.4 North America Anti-Parkinson Drugs Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Anti-Parkinson Drugs Market Size (2015-2020)
• 7.2 Anti-Parkinson Drugs Key Players in Europe (2019-2020)
• 7.3 Europe Anti-Parkinson Drugs Market Size by Type (2015-2020)
• 7.4 Europe Anti-Parkinson Drugs Market Size by Application (2015-2020)

8 China

• 8.1 China Anti-Parkinson Drugs Market Size (2015-2020)
• 8.2 Anti-Parkinson Drugs Key Players in China (2019-2020)
• 8.3 China Anti-Parkinson Drugs Market Size by Type (2015-2020)
• 8.4 China Anti-Parkinson Drugs Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Anti-Parkinson Drugs Market Size (2015-2020)
• 9.2 Anti-Parkinson Drugs Key Players in Japan (2019-2020)
• 9.3 Japan Anti-Parkinson Drugs Market Size by Type (2015-2020)
• 9.4 Japan Anti-Parkinson Drugs Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Anti-Parkinson Drugs Market Size (2015-2020)
• 10.2 Anti-Parkinson Drugs Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Anti-Parkinson Drugs Market Size by Type (2015-2020)
• 10.4 Southeast Asia Anti-Parkinson Drugs Market Size by Application (2015-2020)

11 India

• 11.1 India Anti-Parkinson Drugs Market Size (2015-2020)
• 11.2 Anti-Parkinson Drugs Key Players in India (2019-2020)
• 11.3 India Anti-Parkinson Drugs Market Size by Type (2015-2020)
• 11.4 India Anti-Parkinson Drugs Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Anti-Parkinson Drugs Market Size (2015-2020)
• 12.2 Anti-Parkinson Drugs Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Anti-Parkinson Drugs Market Size by Type (2015-2020)
• 12.4 Central & South America Anti-Parkinson Drugs Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 AbbVie
  • 13.1.1 AbbVie Company Details
  • 13.1.2 AbbVie Business Overview and Its Total Revenue
  • 13.1.3 AbbVie Anti-Parkinson Drugs Introduction
  • 13.1.4 AbbVie Revenue in Anti-Parkinson Drugs Business (2015-2020))
  • 13.1.5 AbbVie Recent Development
• 13.2 Mylan Laboratories
  • 13.2.1 Mylan Laboratories Company Details
  • 13.2.2 Mylan Laboratories Business Overview and Its Total Revenue
  • 13.2.3 Mylan Laboratories Anti-Parkinson Drugs Introduction
  • 13.2.4 Mylan Laboratories Revenue in Anti-Parkinson Drugs Business (2015-2020)
  • 13.2.5 Mylan Laboratories Recent Development
• 13.3 Valeant Pharmaceuticals
  • 13.3.1 Valeant Pharmaceuticals Company Details
  • 13.3.2 Valeant Pharmaceuticals Business Overview and Its Total Revenue
  • 13.3.3 Valeant Pharmaceuticals Anti-Parkinson Drugs Introduction
  • 13.3.4 Valeant Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2015-2020)
  • 13.3.5 Valeant Pharmaceuticals Recent Development
• 13.4 Novartis
  • 13.4.1 Novartis Company Details
  • 13.4.2 Novartis Business Overview and Its Total Revenue
  • 13.4.3 Novartis Anti-Parkinson Drugs Introduction
  • 13.4.4 Novartis Revenue in Anti-Parkinson Drugs Business (2015-2020)
  • 13.4.5 Novartis Recent Development
• 13.5 GlaxoSmithKline
  • 13.5.1 GlaxoSmithKline Company Details
  • 13.5.2 GlaxoSmithKline Business Overview and Its Total Revenue
  • 13.5.3 GlaxoSmithKline Anti-Parkinson Drugs Introduction
  • 13.5.4 GlaxoSmithKline Revenue in Anti-Parkinson Drugs Business (2015-2020)
  • 13.5.5 GlaxoSmithKline Recent Development
• 13.6 Zambon Pharmaceuticals
  • 13.6.1 Zambon Pharmaceuticals Company Details
  • 13.6.2 Zambon Pharmaceuticals Business Overview and Its Total Revenue
  • 13.6.3 Zambon Pharmaceuticals Anti-Parkinson Drugs Introduction
  • 13.6.4 Zambon Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2015-2020)
  • 13.6.5 Zambon Pharmaceuticals Recent Development
• 13.7 Pfizer, Inc.
  • 13.7.1 Pfizer, Inc. Company Details
  • 13.7.2 Pfizer, Inc. Business Overview and Its Total Revenue
  • 13.7.3 Pfizer, Inc. Anti-Parkinson Drugs Introduction
  • 13.7.4 Pfizer, Inc. Revenue in Anti-Parkinson Drugs Business (2015-2020)
  • 13.7.5 Pfizer, Inc. Recent Development
• 13.8 Hoffmann-La Roche
  • 13.8.1 Hoffmann-La Roche Company Details
  • 13.8.2 Hoffmann-La Roche Business Overview and Its Total Revenue
  • 13.8.3 Hoffmann-La Roche Anti-Parkinson Drugs Introduction
  • 13.8.4 Hoffmann-La Roche Revenue in Anti-Parkinson Drugs Business (2015-2020)
  • 13.8.5 Hoffmann-La Roche Recent Development
• 13.9 Merck & Co.
  • 13.9.1 Merck & Co. Company Details
  • 13.9.2 Merck & Co. Business Overview and Its Total Revenue
  • 13.9.3 Merck & Co. Anti-Parkinson Drugs Introduction
  • 13.9.4 Merck & Co. Revenue in Anti-Parkinson Drugs Business (2015-2020)
  • 13.9.5 Merck & Co. Recent Development
• 13.10 Orion Pharma
  • 13.10.1 Orion Pharma Company Details
  • 13.10.2 Orion Pharma Business Overview and Its Total Revenue
  • 13.10.3 Orion Pharma Anti-Parkinson Drugs Introduction
  • 13.10.4 Orion Pharma Revenue in Anti-Parkinson Drugs Business (2015-2020)
  • 13.10.5 Orion Pharma Recent Development
• 13.11 UCB
  • 10.11.1 UCB Company Details
  • 10.11.2 UCB Business Overview and Its Total Revenue
  • 10.11.3 UCB Anti-Parkinson Drugs Introduction
  • 10.11.4 UCB Revenue in Anti-Parkinson Drugs Business (2015-2020)
  • 10.11.5 UCB Recent Development
• 13.12 Teva Pharmaceutical Industries Ltd.
  • 10.12.1 Teva Pharmaceutical Industries Ltd. Company Details
  • 10.12.2 Teva Pharmaceutical Industries Ltd. Business Overview and Its Total Revenue
  • 10.12.3 Teva Pharmaceutical Industries Ltd. Anti-Parkinson Drugs Introduction
  • 10.12.4 Teva Pharmaceutical Industries Ltd. Revenue in Anti-Parkinson Drugs Business (2015-2020)
  • 10.12.5 Teva Pharmaceutical Industries Ltd. Recent Development
• 13.13 Vertical Pharmaceuticals, LLC
  • 10.13.1 Vertical Pharmaceuticals, LLC Company Details
  • 10.13.2 Vertical Pharmaceuticals, LLC Business Overview and Its Total Revenue
  • 10.13.3 Vertical Pharmaceuticals, LLC Anti-Parkinson Drugs Introduction
  • 10.13.4 Vertical Pharmaceuticals, LLC Revenue in Anti-Parkinson Drugs Business (2015-2020)
  • 10.13.5 Vertical Pharmaceuticals, LLC Recent Development
• 13.14 ACADIA Pharmaceuticals Inc.
  • 10.14.1 ACADIA Pharmaceuticals Inc. Company Details
  • 10.14.2 ACADIA Pharmaceuticals Inc. Business Overview and Its Total Revenue
  • 10.14.3 ACADIA Pharmaceuticals Inc. Anti-Parkinson Drugs Introduction
  • 10.14.4 ACADIA Pharmaceuticals Inc. Revenue in Anti-Parkinson Drugs Business (2015-2020)
  • 10.14.5 ACADIA Pharmaceuticals Inc. Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer